Truckee, CA (UroToday.com) - Degarelix is the most widely available and extensively studied gonadotrophin-releasing hormone (GnRH) antagonist for the treatment of advanced prostate cancer (PCa). Degarelix displays a different pharmacological profile to luteinizing hormone-releasing hormone (LHRH) agonists which suggests several potential clinical advantages.
The aim of this article is to propose an algorithm that aids the clinician to choose the best therapeutic scheme of follicle-stimulating hormone (FSH) in the treatment of men with idiopathic infertility, based on testicular volume (TV) and serum total testosterone concentrations; highlighting the potential role of additional therapy with hCG in a sequential temporal scheme.
BACKGROUND: Sex hormones play an important role in the growth and development of the prostate, and low androgen levels have been suggested to carry an adverse prognosis for men with prostate cancer (PCa).
BERKELEY, CA (UroToday.com) - Androgens have historically played an important role in prostate cancer biology and have been a therapeutic target since the early description of androgen deprivation, by Huggins, in 1941.[1]
To explore how follicle-stimulating hormone (FSH) may contribute to cardiovascular, metabolic, skeletal, and cognitive events in men treated for prostate cancer, with various forms of androgen deprivation therapy (ADT).
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
